Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The ideal model in atherosclerosis and dyslipidaemia - does it exist?

Expert opinion on drug discovery·2013
Same author

What is the future for drug development in atherosclerosis and dyslipidaemia?

Expert opinion on drug discovery·2013
Same author

The landscape of drug discovery in atherosclerosis and dyslipidaemia revisited: an update of patenting activity.

Expert opinion on therapeutic patents·2012
Same author

Phospholipase A2s: developing drug targets for atherosclerosis.

Atherosclerosis·2010
Same author

Drug development research: diabetes favored over cardiovascular disease?

Current opinion in investigational drugs (London, England : 2000)·2009
Same author

Animal research: too much faith in models clouds judgement.

Nature·2008

Related Experiment Video

Updated: Jul 5, 2026

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

Selective thyromimetics for atherosclerosis and dyslipidaemia: another old target making progress.

Keith Suckling

    Expert Opinion on Investigational Drugs
    |May 2, 2008
    PubMed
    Summary

    Selective thyromimetics offer a new approach to treating atherosclerosis and dyslipidaemia. Recent human data on eprotirome (KB-2115) show proof of concept, paving the way for further studies.

    Related Experiment Videos

    Last Updated: Jul 5, 2026

    Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
    09:06

    Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

    Published on: February 20, 2019

    Area of Science:

    • Pharmacology and Drug Discovery
    • Cardiovascular Medicine
    • Metabolic Disorders

    Background:

    • Exploiting long-standing drug targets like selective thyromimetics is crucial for advancing therapeutics.
    • Thyromimetics have a history in managing atherosclerosis and dyslipidaemia.
    • Recent research focuses on novel selective thyromimetics, such as eprotirome (KB-2115).

    Discussion:

    • The development of selective thyromimetics represents a targeted approach to lipid management.
    • Eprotirome (KB-2115) has demonstrated proof of mechanism in initial human trials.
    • This class of drugs offers potential for conditions resistant to conventional therapies.

    Key Insights:

    • First human data for eprotirome (KB-2115) confirm its mechanism of action.
    • Selective thyromimetics show promise in addressing unmet needs in dyslipidaemia.
    • The study validates a long-known but previously unexploited drug target.

    Outlook:

    • Further clinical trials are warranted to evaluate eprotirome in broader patient populations.
    • Combination therapy with statins may enhance cardiovascular risk reduction.
    • Selective thyromimetics could become a significant addition to the cardiovascular pharmacopeia.